Shifting paradigms: the seeds of oncogene addiction.
Sawyers
Charles L
CL
Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center and Howard Hughes Medical Institute, New York, New York, USA. sawyersc@mskcc.org
D001363:Awards and Prizes; D001549:Benzamides; D002986:Clinical Trials as Topic; D018076:DNA, Complementary; D004351:Drug Resistance / Q000235:genetics*; D049673:History, 20th Century; D049674:History, 21st Century; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000235:genetics / Q000628:therapy; D009154:Mutation; D009369:Neoplasms / Q000235:genetics* / Q000628:therapy; D009857:Oncogenes / Q000187:drug effects* / Q000235:genetics*; D010879:Piperazines / Q000737:chemistry / Q000627:therapeutic use; D047428:Protein Kinase Inhibitors / Q000737:chemistry / Q000627:therapeutic use; D017434:Protein Structure, Tertiary / Q000235:genetics; D011743:Pyrimidines / Q000737:chemistry / Q000627:therapeutic use; D017422:Sequence Analysis, DNA; D014481:United States
D001549:Benzamides; D018076:DNA, Complementary; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate